Disease Management & Health Outcomes

, Volume 1, Issue 4, pp 185–196 | Cite as

Chronic Heart Failure

Interventions and Outcomes
Review Article Interventions & Outcomes


At a time when death from myocardial infarction, hypertension and stroke is falling, the impact of chronic heart failure (CHF) is escalating relentlessly and it now constitutes a major public health problem. The clinical impact of CHF, both on quality of life and survival is enormous and, because of this, it is also of growing economic importance.

Medical treatment, particularly with ACE inhibitors, improves symptoms and survival rate, and is cost effective. Somewhat surprisingly, ACE inhibitors are still underutilised. Other treatments may also be effective but at present their use in CHF is not clearly defined. Medical therapy in established left ventricular dysfunction may not ultimately be as important as strategies which aim to prevent its occurrence or progression. This article reviews the clinical trials data relating to the effectiveness of current and possible future treatments for CHF.


Digoxin Chronic Heart Failure Enalapril Carvedilol Left Ventricular Dysfunction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Schocken DD, Arrieta MI, Leaverton PE, et al. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol 1992; 20: 301–6PubMedCrossRefGoogle Scholar
  2. 2.
    McMurray J, McDonagh T, Morrison CE, et al. Trends in hospitalisation for heart failure in Scotland 1980–1990. Eur Heart J 1993; 14: 1158–62PubMedCrossRefGoogle Scholar
  3. 3.
    Ho KKL, Pinsky JL, Kannel WB, et al. The epidemiology of heart failure: the Framingham study. J Am Coll Cardiol 1993; 22: 6A–13APubMedCrossRefGoogle Scholar
  4. 4.
    Bourassa MG, Gurne O, Bangdiwala SI, et al. Natural history and patterns of current practice in heart failure. J Am Coll Cardiol 1993; 22: 14A–19APubMedCrossRefGoogle Scholar
  5. 5.
    McMurray J, Hart W. The economic impact of heart failure on the UK National Health Service. Eur Heart J 1993; 14 Suppl.: 133Google Scholar
  6. 6.
    Hart W, McMurray J. The cost-effectiveness of enalapril in the treatment of heart failure. Eur Heart J 1993; 14 Suppl.: 14Google Scholar
  7. 7.
    Mair FS, Crowley TS, Bundred PE. Prevalence, aetiology and management of heart failure in general practice. Br J General Pract 1996; 46: 77–9Google Scholar
  8. 8.
    Houghton AR, Cowley AJ. Effectiveness of a specialist clinic in managing heart failure. J R Coll Physicians Lond. In pressGoogle Scholar
  9. 9.
    Francis CM, Caruana L, Kearney P, et al. Open access echocardiography in management of heart failure in the community. BMJ 1995; 310: 634–6PubMedCrossRefGoogle Scholar
  10. 10.
    Davie AP, Francis CM, Love MP, et al. Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction. BMJ 1996; 312: 222PubMedCrossRefGoogle Scholar
  11. 11.
    Taylor SH. Refocus on diuretics in the treatment of heart failure. Eur Heart J 1995; 16Suppl. F: 7–15PubMedCrossRefGoogle Scholar
  12. 12.
    Cowley AJ, Stainer K, Wynne RD, et al. Symptomatic assessment of patients with heart failure: double blind comparison of increasing doses of diuretics and Captopril in moderate heart failure. Lancet 1986; II: 770–2CrossRefGoogle Scholar
  13. 13.
    Grinstead WC, Francis MJ, Marks GF, et al. Discontinuation of chronic diuretic therapy in stable congestive heart failure secondary to coronary artery disease or to idiopathic dilated cardiomyopathy. Am J Cardiol 1994; 73: 881–6PubMedCrossRefGoogle Scholar
  14. 14.
    Pitt B. ACE inhibitor co-therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES). Eur Heart J 1995; 16Suppl. N: 107–10PubMedCrossRefGoogle Scholar
  15. 15.
    Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Co-operative Study (V-HeFT). N Engl J Med 1986; 314: 1547–52PubMedCrossRefGoogle Scholar
  16. 16.
    Cohn JN, Johnson G, Ziesche S, et al. A comparison of Enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303–10PubMedCrossRefGoogle Scholar
  17. 17.
    Walsh JT, Andrews R, Cowley AJ. Effects of amlodipine in chronic heart failure. Am Heart J. In pressGoogle Scholar
  18. 18.
    Packer M, O’Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335: 1107–14PubMedCrossRefGoogle Scholar
  19. 19.
    The CONSENSUS Trial Study Group. Effect of enalapril on mortality in severe heart failure. N Engl J Med 1987; 316: 1429–35CrossRefGoogle Scholar
  20. 20.
    The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 295–302Google Scholar
  21. 21.
    Rogers WJ, Johnstone DE, Yusuf S, et al. Quality of life among 5025 patients with left ventricular dysfunction randomised between placebo and enalapril: SOLVD. J Am Coll Cardiol 1994; 23: 393–400PubMedCrossRefGoogle Scholar
  22. 22.
    The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685–91CrossRefGoogle Scholar
  23. 23.
    Cowley AJ, Hampton JR, Rowley JM, et al. Abnormalities of peripheral circulation and respiratory function in patients with severe heart failure. Br Heart J 1986; 55: 75–80PubMedCrossRefGoogle Scholar
  24. 24.
    Pfeffer MA, Braunwald E, Moye LA, et al. Effect of Captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial dysfunction. N Engl J Med 1992; 327: 669–77PubMedCrossRefGoogle Scholar
  25. 25.
    The AIRE Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821–8Google Scholar
  26. 26.
    Kober L, Torp-Pederson C, Carlsen JE, et al. A clinical trial of the angiotensin converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670–6PubMedCrossRefGoogle Scholar
  27. 27.
    The ISIS-4 Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral Captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected myocardial infarction. Lancet 1995; 345: 669–84CrossRefGoogle Scholar
  28. 28.
    GISSI-3 Collaborators. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6 week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115–22Google Scholar
  29. 29.
    Fiather M. From infarct to failure: meta-analysis of ACE-inhibitor trials in myocardial infarction. Oral presentation at 18th Congress of European Society of Cardiology: 1996 Aug 25–29; BirminghamGoogle Scholar
  30. 30.
    Benedict C, Rousseau M, Bourassa M, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992; 340: 1173–8PubMedCrossRefGoogle Scholar
  31. 31.
    MERCATOR Study Group. Does the new angiotensin converting enzyme inhibitor Cilazapril prevent restenosis after percutaneous transluminal angioplasty? Circulation 1992; 86: 100–10CrossRefGoogle Scholar
  32. 32.
    Mancini GBJ, Henry GC, Macaya C, et al. Angiotensin converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND study. Circulation 1996; 94: 258–65PubMedCrossRefGoogle Scholar
  33. 33.
    Texter M, Lees RS, Pitt B, et al. The Quinapril Ischaemic Event Trial (QUIET). Cardiovasc Drugs Ther 1993; 7: 273–82PubMedCrossRefGoogle Scholar
  34. 34.
    The NETWORK Investigators. The NETWORK study: the effect of dose of an ACE inhibitor on outcome in patients with heart failure. Heart 1996; 75 Suppl.: P54Google Scholar
  35. 35.
    Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993; 342: 1441–6PubMedCrossRefGoogle Scholar
  36. 36.
    CIBIS Investigators. A randomised trial of β-blockade in heart failure: the cardiac insufficiency bisoprolol study. Circ 1994; 90: 1765–73CrossRefGoogle Scholar
  37. 37.
    Packer M, Bristow MR, Cohn JN, et al. The effect of Carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349–55PubMedCrossRefGoogle Scholar
  38. 38.
    Packer M, Colucci WS, Sackner-Bernstein JD, et al. Doubleblind, placebo-controlled study of the effects of Carvedilol in patients with moderate-severe heart failure: the PRECISE Trial. Circulation 1996; 94: 2793–9PubMedCrossRefGoogle Scholar
  39. 39.
    Cowley AJ, Skene AM. Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Br Heart J 1994; 72: 226–30PubMedCrossRefGoogle Scholar
  40. 40.
    Packer M, Rouleau J, Swedberg K, et al. Effect of flosequinan on survival in chronic heart failure: preliminary results of the PROFILE study. Circulation 1993; 88: 1–301Google Scholar
  41. 41.
    Hampton JR, Van Veldhuisen DJ, Kleber FX, et al. Randomised study of the effect of ibopamine on survival in patients with advanced severe heart failure. Lancet 1997; 349: 971–7PubMedCrossRefGoogle Scholar
  42. 42.
    Feldman A, Young J, Bourge R, et al. Mechanism of increased mortality from vesnarinone in the severe heart failure trial (VesT). J Am Coll Cardiol 1997; 29Suppl. A: 64AGoogle Scholar
  43. 43.
    Uretsky BF, Young JB, Shahidi E, et al. Randomised study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. J Am Coll Cardiol 1993; 22: 955–62PubMedCrossRefGoogle Scholar
  44. 44.
    Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin converting enzyme inhibitors. N Engl J Med 1993; 329: 1–7PubMedCrossRefGoogle Scholar
  45. 45.
    The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl JMed 1997; 336: 525–32CrossRefGoogle Scholar
  46. 46.
    Doval HC, Nul DR, Grancelli HO, et al. Randomised trial of low dose amiodarone in severe congestive heart failure. Lancet 1994; 344: 493–8PubMedCrossRefGoogle Scholar
  47. 47.
    Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995; 333: 77–82PubMedCrossRefGoogle Scholar
  48. 48.
    Waldo AL, Camm AJ, de Ruyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996; 348: 7–12PubMedCrossRefGoogle Scholar
  49. 49.
    Newman D, Sauve MJ, Herre J, et al. Survival after implantation of the cardiac defibrillator. Am J Cardiol 1992; 69: 899–903PubMedCrossRefGoogle Scholar
  50. 50.
    Pitt B, Segal R, Martinez FA, et al. Randomized trial of losartan versus Captopril in patients over 65 with heart failure (Evaluation of Losartan In The Elderly study, ELITE). Lancet 1997; 349: 747–52PubMedCrossRefGoogle Scholar
  51. 51.
    O’Connell JB, Breen TJ, Hosenpud JD. Heart transplantation in dilated heart muscle disease and myocarditis. Eur Heart J 1995; 16Suppl. O: 137–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1997

Authors and Affiliations

  1. 1.Department of Cardiovascular MedicineUniversity HospitalNottinghamEngland

Personalised recommendations